The molecular targets for trace amines (TAs) such as p-tyramine and β-phenylethylamine have been recently discovered and have been shown to comprise a family of G-protein-coupled receptors based on DNA sequence homologies. These have been termed trace amine-associated receptors (TAARs) because TAs do not activate all of the identified receptors. Because TA may be involved in modulating a variety of behaviors including mood, cognition, and addiction, it is of interest to discover novel ligands for TAARs to probe the role TAs play in brain function. Pharmacophore development for the G s -coupled human TAAR1 (hTAAR1) would be aided by a rapid functional assay amenable to screening libraries of compounds. Accordingly, the authors used RD-HGA16 CHO-1 cells from Molecular Devices, which stably express the promiscuous G q , G α16 , to create a cell line stably expressing hTAAR1, thereby coupling receptor activation to the mobilization of internal calcium. They used this cell line to develop a homogenous fluorometric imaging plate reader-based assay using the Calcium 3 fluorescent dye. The EC 50 and E max data obtained for known TAs are in close agreement with previous work using transient hTAAR1 expression systems or a chimeric receptor. These data indicate that the hTAAR1 retains its reported pharmacological characteristics when coupled to G α16 . (Journal of Biomolecular Screening 2006:688-693) 
INTRODUCTION
β -PHENETHYLAMINE (β-PEA) and p-tyramine (TYR) have been know to exert pharmacological actions in humans. 1, 2 These and other compounds such as octopamine and tryptamine are known as trace amines (TAs) and are present in nanomolar concentrations in the mammalian brain. TAs are of particular interest because they have been shown to modulate the activity of neurotransmitters such as dopamine [3] [4] [5] and γ-amino butyric acid, [6] [7] [8] and alterations in their brain levels are associated with schizophrenia [9] [10] [11] and depression. 12, 13 Their potential to modulate dopaminergic activity suggests that they may play a role in the efficacy of L-DOPA in treating Parkinson disease 4 and addiction. 5 Systematic study of the role of TAs in brain function and disease has begun in earnest since the recent discovery of a novel family of G-protein-coupled receptors through which these compounds act. [14] [15] [16] These are putative 7 TM receptors with high homology to other G-protein-coupled receptors. In humans, only TA receptor 1 has been shown to be activated by β-PEA and TYR, resulting in increased cyclic adenosine monophosphate (cAMP) accumulation through coupling to G s . 16 This has given rise to the term trace amine-associated receptors (TAARs) to describe this family. 16 In addition to binding β-PEA and TYR, rat TAAR1 is also activated by dopamine, octopamine, tryptamine, amphetamine, and lysergic acid. 15 The human TAAR1 (hTAAR1) is undergoing pharmacological characterization. 17 The variety of compounds potentially acting at this receptor makes it attractive to assume that hTAAR1 is involved in a variety of integrated CNS processes such as mood and cognition. Because of this, hTAAR1 is an interesting target for the development of ligands to probe the role of this receptor in CNS function and disease. Current assays for hTAAR1 activation measure cAMP levels and use transiently expressed receptor 14 or a stably expressed humanrat chimera. 16 The discovery of new ligands for the hTAAR1 would be greatly facilitated by a rapid functional assay of the native human receptor that is amenable to high-throughput screening. Accordingly, we report the creation of 2 stable cell lines that express the unmodified hTAAR1. In one of the cell lines, CHO-K1 cells stably express the hTAAR1 linked to the G s signaling pathway. In the other, RD-HGA16 cells were stably transfected with the receptor. The RD-HGA16 is a CHO cell line that expresses the promiscuous G q G α1618 and permits the coupling of non-G q -coupled G-protein-coupled receptors to the mobilization of internal calcium. We used this cell line to develop a high-throughput-compatible functional assay for the activation of hTAAR1.
MATERIALS AND METHODS hTAAR1 expression plasmid and stably transfected cell lines
hTAAR1 cDNA was cloned from Marathon Ready cDNA from human stomach using the Advantage cDNA PCR kit, both from Clonetech (Mountain View, CA). The receptor was amplified in 2 parts using primer pairs based on published information 14 and genbank accession no. AF380185. The 2-part strategy was used because we had difficulty obtaining the full-length DNA with 1 set of primers. Primers used were 5′ATGATG-CCCTTTTGCCACAATATAATTAATATTTCCTGTGTGAAA AACAACTGGTCAAATGATGTCCGTGCTTCCC 3′ and 5′ CCATCACAATCCCCAATGTCTTCACAGC 3′ to amplify bases 1 to 772 and 5′CTATGAACTCAATTCCAAAAATAATTTA-
C AC C T G G AT G A AT C T T T T T G G A A A AT T T TAC -CAAACAGCATCATCTTCAGTGCTTTTCTAAACCAAGG
3′ and 5′ CATGGCCACTGTGGACTTTCTTCTGGGG 3′ to amplify bases 192 to 1020. The resultant PCR products were subcloned separately into the pcDNA4/HisMax TOPO TA expression vector (Invitrogen, Carlsbad, CA). The cloned PCR products were verified by sequence analysis (Duke University DNA Analysis Facility, Durham, NC). The full-length hTAAR1 cDNA was generated by restriction digestion of the 5′ and 3′ cDNAs with EcoRV/PstI and SmaI/PstI, respectively, and subsequent subcloning into the pcDNA4/HisMax TOPO TA expression vector. Upon reconsideration, we believed that the N-terminal 6x his tag in this vector might interfere with intracellular trafficking of the receptor. We therefore subcloned the coding region into an expression vector without an N-terminal tag. The full-length hTAAR1 coding sequence without an N-terminal epitope tag was generated by PCR of this construct. The primer pairs used, 5′ ATAGGATCCACCATGATGCCCTTTTGCC 3′ and 5′ TAT-GAATTCCTATGAACTCAATTCCAAAAAT 3′, introduce a Kozak consensus sequence and incorporate restriction enzyme sites BamHI (5′) and EcoRI (3′). These sites were used to subclone hTAAR1 coding sequence into a mammalian expression vector containing the EF-1.2 promoter, a neomycin resistance gene, and a C-terminal Ha epitope tag (a kind gift from Dr. Ramón Trullas, Institut d'Investigacions Biomediques de Barcelona, Barcelona, Spain). The endogenous stop codon of hTAAR1 is included so the Ha tag is not incorporated into the expressed hTAAR1 protein.
Plasmid DNA from the resulting construct was prepared using Qiagen's Hispeed plasmid purification kit as per the manufacturer's instructions. The sequence was verified, and DNA was linearized by ScaI digestion prior to transfection of cells. The hTAAR1 expression construct was transfected into CHO-K1 cells (ATCC) using Lipofectamine 2000 (Invitrogen) as per the manufacturer's instructions. Stable transfectants were selected in 400 µg/ml geneticin and subsequently analyzed for increased cAMP accumulation in response to β-PEA using the cAMP Direct Biotrak EIA (Amersham Biosciences, Piscataway, NJ) as per the manufacturer's instructions. Three positive clones were selected for further experiments. The hTAAR1 construct was also stably expressed in CHO-derived RD-HGA16 cells (Molecular Devices Corporation, Sunnyvale, CA). RD-HGA16 cells stably express the promiscuous G q protein G α16 . Expression of G α16 allows coupling of hTAAR1 to calcium mobilization. These cells were transfected with the hTAAR1 expression construct using Lipofectamine 2000 reagent as per the manufacturer's instructions. Stably transfected cells were selected in 400 µg/ml geneticin (hTAAR1 selection) and 400 µg/ml hygromycin (G α16 selection). Clones were selected from low-density cultures and analyzed for response to β-PEA using the Calcium 3 assay and a FlexStation (FlexStation II 384 ; Molecular Devices Corporation) as per the manufacturer's instructions. Three positive clones were chosen for further experiments based on their positive response to β-PEA. All data are from 1 clonal line of hTAAR1/CHO-K1 cells or hTAAR1/RD-HGA16 cells.
cAMP accumulation assay
The ability of test compounds to stimulate adenylyl cyclase via G s -coupled hTAAR1 was determined in the CHO-K1 hTAAR1 cells using the cAMP Direct Biotrak EIA Kit (Amersham Biosciences). The assay was conducted according to the manufacturer's specifications, and absorbance was measured with the FlexStation. Test compounds were evaluated at 8 different concentrations assayed in duplicate, and the final assay DMSO concentration was 0.5%.
Calcium flux assay
TA receptor activation was assayed in CHO cells stably expressing G α16 and the hTAAR1 receptor. These cells were plated in HAM's F-12 medium with 10% fetal bovine serum, 400 µg/ml hygromycin, and 400 µg/ml geneticin at 30,000 cells/well in 96-well, black, clear-bottom plates and incubated at 37 °C 5% CO 2 overnight. Activation of hTAAR1 via test compounds was assessed the next day using the Calcium 3 Assay Kit (Molecular Devices). On the day of assay, the culture medium was removed and the cells washed once in 100 µl HBSS buffer containing 0.78 mg/ml probenicid, followed by the addition of 100 µl HBSS buffer plus probenicid and 100 µl of Calcium 3 dye (one-third the suggested concentration). The cells were incubated with the dye at 37 °C for 1 h. Test compounds were evaluated using 10 different concentrations run in duplicate. These were added to cells at 5 times the final concentration in HBSS/probenicid containing 1.25% DMSO (0.25% final concentration). The effect of test compound on internal calcium mobilization was determined with a FlexStation set for bottom read with 485-nm excitation and 525-nm emission wavelengths and a 515-nm emission cutoff. Data were captured using SoftmaxPro (Molecular Devices), and max-min was used to calculate the change in fluorescence intensity.
Data analysis
A 3-parameter logistic equation was fit to the data to calculate the EC 50 and E max values (Prism version 4.0; GraphPad, Inc., San Diego, CA). Data are reported as the mean ± SEM from at least 3 to 5 separate experiments. The E max values were compared using 1-way ANOVA (Prism) followed by Dunnett's post hoc test, which compared test values to β-PEA. The post hoc test was run only if the 1-way ANOVA was significant, and significance was assumed at p < 0.05.
RESULTS

hTAAR1/CHO-K1 cells
The expression plasmid coding for unmodified hTAAR1 was transfected into CHO-K1 cells to create cell lines stably expressing the receptor. Receptor-positive clones were selected by cAMP assay following exposure to 10 µM of the hTAAR1 agonist β-PEA. Of 71 clones screened, the 3 clones exhibiting the highest cAMP levels were chosen for further analysis. EC 50 values for β-PEA were determined for each of these 3 clones, and the 1 clone exhibiting the lowest EC 50 was chosen for all subsequent experiments.
We routinely determine the sensitivity of cell lines to various DMSO concentrations because library compounds are typically dissolved in 100% DMSO prior to assay. The response of this cell line to β-PEA was not adversely affected by final DMSO concentrations up to 1% (data not shown). A set of known hTAAR1 agonists was run against this cell line at a 1% DMSO final concentration. β-PEA and TYR were full agonists, with EC 50 values of 1.9 ± 0.5 and 5.4 ± 0.6 µM, respectively. The EC 50 values for octopamine, dopamine, and tryptamine were each >10 µM.
hTAAR1/CHO-G α α16 cells
The expression plasmid coding for unmodified hTAAR1 was transfected into a CHO cell line that stably expresses the promiscuous G q subunit G α16 . To determine whether activation of hTAAR1 expressed in these cells was functionally coupled to G α16 , cells were screened for calcium mobilization using a calcium-sensitive dye in a fluorometric imaging plate reader (FLIPR)-based assay. Calcium transients were assayed in a 96-well format using a FlexStation and Calcium 3 dye. The homogeneous format of this functional assay (i.e., no processing of the assay sample was necessary before the data were collected) allowed us to screen more than 200 clones. Of these, 3 clones gave a greater than 5000 relative fluorescence unit increase over basal values in response to 10 µM β-PEA. EC 50 values were determined for these 3 clones, and the one with the lowest EC 50 was selected for further work because all 3 clones gave similar stimulation of basal fluorescence. A typical calcium trace for β-PEA in this cell line is shown in Figure 1 . β-PEA-stimulated mobilization of internal calcium was apparent 7 to 8 s after the addition of compound and peaked 15 to 20 s later.
The DMSO sensitivity of this cell line was determined by comparing β-PEA concentration response curves run with final DMSO concentrations ranging from 0% to 2% (Fig. 2) . Increasing DMSO concentrations to ≥0.5% resulted in a leftward shift in the β-PEA concentration response curves and an increase in basal fluorescence such that a final concentration of 2% DMSO produced a fluorescence intensity nearly equal to that of 10 µM β-PEA. However, 0.25% DMSO did not alter basal fluorescence or the response of the cells to β-PEA. The performance of various concentrations of the Calcium 3 dye was also determined. Cells were loaded with 1 times, one-half times, or onefourth times the recommended dye concentration prior to assay. A one-fourth times concentration yielded excellent results (data not shown); thus, subsequent assays were performed with a final DMSO concentration of 0.25% and one-fourth times calcium dye concentration.
To investigate whether the coupling of hTAAR1 to G α16 has any effect on receptor pharmacology, the EC 50 and E max values for a set of known hTAAR1 biogenic amine agonists of various potencies were determined (Fig. 3, Table 1 ). Similar to what was observed in the hTAAR1/CHO-K1 cells, the 2 most potent compounds were β-PEA and TYR. However, their EC 50 values in the hTAAR1/CHO-G α16 cells were an order of magnitude lower than what was measured in hTAAR1/CHO-K1 cells. This leftward shift in the concentration-response curves permitted the determination of the EC 50 and E max values for dopamine, octopamine, and tryptamine. All 3 compounds had similar potency, with octopamine and dopamine being full agonists at hTAAR1 whereas tryptamine was a partial agonist when compared to the full agonist β-PEA (F = 3.17 4, 15 ; p < 0.05; Dunnett's test). Because of the results with tryptamine, the ability of serotonin to activate hTAAR1 was tested. Serotonin was considerably less potent than tryptamine, with an EC 50 value estimated to be >200 µM.
DISCUSSION
The results of this study show that the unmodified hTAAR1 can be stably expressed in CHO-K1 cells and that activation of the receptor can be coupled to the mobilization of internal calcium stores through G α16 . To our knowledge, these are the first cell lines stably expressing the unmodified hTAAR1. Coupling the hTAAR1 to calcium mobilization permits the development of a homogeneous assay that can be used to rapidly screen compounds for activity at the hTAAR1. However, for this assay to be useful in the discovery of novel hTAAR1 compounds, it must respond appropriately to known hTAAR1 ligands. The known pharmacology of this receptor is based only on artificial test systems in which the receptor has been transiently expressed unmodified in COS-7 cells 14 or stably expressed in HEK 293 cells as a human-rat chimera. 16 As can be seen in Table 1 , the EC 50 and E max values determined for various biogenic amines in our calcium flux assay compare well with those reported in the transient and stable cell lines that used cAMP accumulation as the end point. However, the intrinsic activity for dopamine and tryptamine were different from those reported by Lindemann and others, 16 namely, we found dopamine was a full agonist and tryptamine a partial agonist at the hTAAR1. That differences were found is not surprising given that the receptor studied by Lindemann and others 16 is a chimera and the alterations in the hTAAR1 sequence could cause structural changes in the protein that modifies its response to ligands, its coupling to G s , or both. It has also been reported that rat and TAAR1 couple differently to G s and that the activation of human hTAAR1 can be enhanced via coexpression with G s . 19 Last, our hTAAR1 is coupled to G α16 , and it is possible that the receptor conformation imposed by the binding of an agonist is not optimal for the different G α subunits. Thus, the environment in which the receptor is expressed could alter its response to ligands. Despite these differences, hTAAR1 appears to retain normal pharmacological behavior when coupled to G α16 and the mobilization of internal calcium in hTAAR1/CHO-G α16 cells. Differences in assay technology could also cause differential responses to ligands. For example, in the FLIPR-based calcium flux assay we used, the compounds interact with the receptor for a brief (∼50 s) period. These are nonequilibrium conditions, and compound on and off rates can significantly affect the results. For example, an antagonist with a slow off rate could appear as a noncompetitive antagonist under these assay conditions even with a brief preincubation period. The relatively brief exposure time could also make it difficult to identify inverse agonists provided the receptor is constitutively active. Thus, a secondary screen in which the compound is tested with the receptor coupled to the G s subunit and a longer incubation period would be needed to better characterize interesting compounds. Nevertheless, the calcium flux assay we describe for the hTAAR1 should be useful for the rapid screening of compound libraries.
We also found that in CHO-K1 cells, the agonist doseresponse curves for cAMP accumulation were shifted to the right by an order of magnitude compared to those reported by Borowsky and others 14 and Lindemann and others. 16 The rightward shift in the concentration response curves made it difficult to characterize the EC 50 and E max values of low-potency compounds such as tryptamine and octopamine because of their limited solubility in DMSO. An assay that detects only high-potency compounds is not useful for the screening of compound libraries in which interesting hits could have weak activity (e.g., 50% stimulation of cAMP at 10 µM). Concentration response curves for these same agonists displayed a 10-fold leftward shift when assayed in the hTAAR1/CHO-G α16 cells. This leftward shift could be due to an increased probability of receptor-effector coupling in the G α16 clone and suggests that in the CHO-K1 cells, G s levels may limit hTAAR1 activation and its coexpression and that G s in CHO-K1 could improve the performance of the cAMP assay. 19 In keeping with this, the EC 50 values of the full kappa agonists U69,593 and the nonalkaloid natural product salvinorin A show a similar trend when assayed at the human kappa opioid receptor (hKOR) stably expressed in CHO-K1 cells or in hKOR/CHO-G α16 cells using the [ 35 S]GTP-γ-S binding or the calcium flux assay, respectively. 20 In this study, the EC 50 values determined using the hKOR/CHO-G α16 cells were 30 to 50 times lower than those measured using the CHO-K1. These data also suggest that relatively low target expression may be desirable for functional assays because it increases the probability of receptoreffector coupling and the presence of spare receptors.
In conclusion, we have developed a rapid plate-based homogeneous assay for the unmodified hTAAR1 coupled to mobilization of internal calcium. The assay response to known ligands and its sensitivity are similar to that observed for other cell-based assay systems using cAMP as the end point. Because the hTAAR1 is stably expressed, it is more likely that the assay performance will remain consistent over time compared to different batches of transiently transfected cells, an important factor considering compound screening campaigns and lead development typically extend over several years.
